What Aggravates Ankylosing Spondylitis?
Title: What Aggravates Ankylosing Spondylitis?Category: Diseases and ConditionsCreated: 7/22/2021 12:00:00 AMLast Editorial Review: 7/22/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 22, 2021 Category: Rheumatology Source Type: news

Can You Live Long with Ankylosing Spondylitis
Can You Live a Long Life with Ankylosing Spondylitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 22, 2021 Category: General Medicine Source Type: news

Can Surgery Help Ankylosing Spondylitis (AS)?
Title: Can Surgery Help Ankylosing Spondylitis (AS)?Category: Diseases and ConditionsCreated: 7/20/2021 12:00:00 AMLast Editorial Review: 7/20/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 20, 2021 Category: Rheumatology Source Type: news

What Is the Best Diet for Ankylosing Spondylitis (AS)?
Title: What Is the Best Diet for Ankylosing Spondylitis (AS)?Category: Diseases and ConditionsCreated: 7/20/2021 12:00:00 AMLast Editorial Review: 7/20/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 20, 2021 Category: Rheumatology Source Type: news

Is Ankylosing Spondylitis Treatment Permanent Cure
Is Ankylosing Spondylitis Treatment a Permanent Cure? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2021 Category: General Medicine Source Type: news

What Helps Ankylosing Spondylitis Pain
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 15, 2021 Category: General Medicine Source Type: news

Can Surgery Help Ankylosing Spondylitis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 15, 2021 Category: General Medicine Source Type: news

What Triggers Ankylosing Spondylitis (AS)?
Title: What Triggers Ankylosing Spondylitis (AS)?Category: Diseases and ConditionsCreated: 7/14/2021 12:00:00 AMLast Editorial Review: 7/14/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 14, 2021 Category: Rheumatology Source Type: news

What Is the Best Medication for Ankylosing Spondylitis (AS)?
Title: What Is the Best Medication for Ankylosing Spondylitis (AS)?Category: Diseases and ConditionsCreated: 7/14/2021 12:00:00 AMLast Editorial Review: 7/14/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 14, 2021 Category: Drugs & Pharmacology Source Type: news

How Do Doctors Test for Ankylosing Spondylitis?
Title: How Do Doctors Test for Ankylosing Spondylitis?Category: Health and LivingCreated: 6/9/2021 12:00:00 AMLast Editorial Review: 6/9/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 9, 2021 Category: Rheumatology Source Type: news

Endurance Athlete Living with Ankylosing Spondylitis Undertakes...
On August 13, 2021, Helgi Olafson, a health activist, professional yacht chef, and endurance athlete living with ankylosing spondylitis, will kick off the Triple Crown of 200s, three original...(PRWeb June 07, 2021)Read the full story at https://www.prweb.com/releases/endurance_athlete_living_with_ankylosing_spondylitis_undertakes_2_855_mile_journey_to_benefit_spondylitis_association_of_america/prweb17984297.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 7, 2021 Category: Pharmaceuticals Source Type: news

What Is Best Treatment for Ankylosing Spondylitis
What Is the Best Treatment for Ankylosing Spondylitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 4, 2021 Category: General Medicine Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Arthritis: The best type of diet to ease inflammation in the body – what to eat
ARTHRITIS caused by misdirected inflammation include rheumatoid, psoriatic, systemic lupus erythematosus, gout and ankylosing spondylitis. Could an anti-inflammatory diet help ease symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - May 6, 2021 Category: Consumer Health News Source Type: news

How Do You Permanently Cure Ankylosing Spondylitis?
Title: How Do You Permanently Cure Ankylosing Spondylitis?Category: Diseases and ConditionsCreated: 5/5/2021 12:00:00 AMLast Editorial Review: 5/5/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 5, 2021 Category: Rheumatology Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Triggers Ankylosing Spondylitis Symptoms
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 16, 2021 Category: General Medicine Source Type: news

Is Ankylosing Spondylitis an Autoimmune Disease
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 14, 2021 Category: General Medicine Source Type: news

Is Turmeric Good for Ankylosing Spondylitis?
Title: Is Turmeric Good for Ankylosing Spondylitis?Category: Diseases and ConditionsCreated: 4/5/2021 12:00:00 AMLast Editorial Review: 4/5/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 5, 2021 Category: Rheumatology Source Type: news

Ankylosing Spondylitis: The Long Hunt for a Right Diagnosis
Ankylosing spondylitis (AS) is a rare type of arthritis in the spine whose main symptom -- back pain -- is a common, everyday complaint. That’s just one reason why so many people with AS wait years for a correct diagnosis. (Source: WebMD Health)
Source: WebMD Health - January 8, 2021 Category: Consumer Health News Source Type: news

What We Learned From Pain of Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a disease that can upend lives. Learn how two people ultimately found a way to forge ahead after their diagnoses. (Source: WebMD Health)
Source: WebMD Health - December 22, 2020 Category: Consumer Health News Source Type: news

CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoi... Biopharmaceuticals, Regulatory AbbVie, RINVOQ, upadacitinib, psoriatic arthritis, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3 Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
The oral JAK inhibitor was significantly more effective than placebo at primary and secondary endpoints. Safety risks were comparable to those seen in the treatment of rheumatoid and psoriatic arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Tumor Necrosis Factor Alpha Inhibitors May Pose Risk in Ankylosing Spondylitis and Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 21, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

IL-17 Inhibitors in the Treatment of Ankylosing Spondylitis IL-17 Inhibitors in the Treatment of Ankylosing Spondylitis
Several IL-17 inhibitors are approved for the treatment of ankylosing spondylitis, but what do we know about the safety and efficacy of these drugs?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Some Biologics Better Than Others for Averting Anterior Uveitis Some Biologics Better Than Others for Averting Anterior Uveitis
For patients with ankylosing spondylitis or undifferentiated spondyloarthritis, risk for anterior uveitis hinges by disease-modifying antirheumatic drug, a large Swedish cohort study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA
The monoclonal interleukin-17A antagonist has three other indications: ankylosing spondylitis in adults, psoriatic arthritis in adults, and plaque psoriasis in adults and children age 6 and older.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 1, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA INDIANAPOLIS, June 1, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company ... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, spondyloarthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2020 Category: Pharmaceuticals Source Type: news

What Are Early Symptoms of Ankylosing Spondylitis
What Are the Early Symptoms of Ankylosing Spondylitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 22, 2020 Category: General Medicine Source Type: news

‘This Is Really Life or Death.’ For People With Disabilities, Coronavirus Is Making It Harder Than Ever to Receive Care
Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a c...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

The risk of deliberate self-harm following a diagnosis of rheumatoid arthritis or ankylosing spondylitis: a population-based cohort study - Kuriya B, Vigod S, Luo J, Widdifield J, Haroon N.
OBJECTIVE: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with mental illness. The risk of serious mental illness, including deliberate self-harm (DSH), in these conditions is not well known. We aimed to determine if RA or AS inde... (Source: SafetyLit)
Source: SafetyLit - February 25, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Factors That Predict Radiographic Progression of Ankylosing Spondylitis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - February 15, 2020 Category: Orthopaedics Tags: CME Article Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Humid, Windy Days Worse For Pain, Says New Study
(CNN) — Humid, windy days with low pressure make pain worse in those with long-term health conditions, according to new research. People with conditions like arthritis, fibromyalgia, migraine and neuropathic pain are 20% more likely to suffer pain in such weather, reveals a study carried out by scientists from the University of Manchester, UK. “This would mean that, if your chances of a painful day on an average weather day were 5 in 100, they would increase to 6 in 100 on a damp and windy day,” said study author Will Dixon, professor of Digital Epidemiology, in a statement. Relatively high humidity is th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated CBSN Boston CNN Pain Study Source Type: news

Smoking Cessation Effects in Ankylosing Spondylitis Smoking Cessation Effects in Ankylosing Spondylitis
Ankylosing spondylitis patients who quit smoking may realize improvements in disease activity, mobility, and quality of life.Journal of Clinical Rheumatology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 21, 2019 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

CARD9 mediates dendritic cell-induced development of Lyn deficiency-associated autoimmune and inflammatory diseases
CARD9 is an immune adaptor protein in myeloid cells that is involved in C-type lectin signaling and antifungal immunity. CARD9 is implicated in autoimmune and inflammatory-related diseases, such as rheumatoid arthritis, IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (IBD). Given that Lyn-deficient (Lyn–/–) mice are susceptible to both autoimmunity and IBD, we investigated the immunological role of CARD9 in the development of these diseases using the Lyn–/– mouse model. We found that genetic deletion of CARD9 was sufficient to reduce the development of both spontaneous autoim...
Source: Signal Transduction Knowledge Environment - October 7, 2019 Category: Science Authors: Ma, J., Abram, C. L., Hu, Y., Lowell, C. A. Tags: STKE Research Articles Source Type: news

Treatment Guidelines Updated for Ankylosing Spondylitis, Axial SpA
WEDNESDAY, Aug. 28, 2019 -- In a special article published online Aug. 21 in Arthritis Care& Research, the American College of Rheumatology, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network present... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 26, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 26, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news

Effects of Infliximab Withdrawal and Reintroduction in Ankylosing Spondylitis Patients in Persistent Clinical Remission
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 15, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Withdrawal of Infliximab Therapy in Ankylosing Spondylitis Withdrawal of Infliximab Therapy in Ankylosing Spondylitis
Should infliximab withdrawal be considered for ankylosing spondylitis patients who have achieved clinical remission? What are the effects of reintroduction?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Psoriatic Spondylitis or Ankylosing Spondylitis Psoriasis Psoriatic Spondylitis or Ankylosing Spondylitis Psoriasis
A new review examines the similarities and differences between these conditions, and explores the implications for treatment.Current Opinion in Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Venous Thromboembolism Risk High in Ankylosing Spondylitis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - May 15, 2019 Category: Orthopaedics Tags: Snapshot Source Type: news

FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news

Ankylosing Spondylitis and Health-Related Quality of Life
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - April 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Why do patients turn to the internet for health information?
Lack of trust in physicians, lack of information about biologics, medicine substitutions and the search for alternative therapies are among the reasons patients turn to the internet, a new study shows. (Source: ConsultantLive)
Source: ConsultantLive - March 5, 2019 Category: Internal Medicine Authors: Whitney J. Palmer Tags: Ankylosing Spondylitis Source Type: news

VTE Risk High in Ankylosing Spondylitis (CME/CE)
(MedPage Today) -- Risk of DVT significantly elevated; less risk seen for PE (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 25, 2019 Category: Primary Care Source Type: news